Qsymia 11.25Mg-69Mg Extended Release Capsule + Qsymia 15Mg-92Mg Extended Release Capsule + Qsymia 3.75Mg-23Mg Extended Release Capsule + Qsymia 7.5Mg-46Mg Extended Release Capsule for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 17 Sep 2021: Trial started, NCT05378503
  2. 18 May 2022: Trial registered, NCT05378503

The trials

NCT05378503: Phase IV Study of Qsymia in Obese Patients

State
Completed
Phase
Phase 4
People
232 taking part
Started
17 Sep 2021
Primary completion
30 Oct 2023
Arms
Active
Results
None posted
  1. 17 Sep 2021: Trial started
  2. 18 May 2022: Trial registered
  3. 30 Oct 2023: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.